Image may be NSFW.
Clik here to view.
Glaukos (NYSE:GKOS) has inked a research & development deal with Japanese biotech D. Western Therapeutics Institute to develop an intraocular glaucoma therapy.
Glaukos and DWTI plan to evaluate products from the biotech’s compound library, as well as potentially synthesize new compounds as a part of the collaboration.
Get the full story at our sister site, Drug Delivery Business News.
The post Glaukos inks R&D deal for glaucoma therapy appeared first on MassDevice.
